- Second-quarter adjusted EPS for Thermo Fisher came in at $5.36, slightly down from $5.37 year-on-year, but exceeded the estimate of $5.24.
- Revenue was reported at $10.86 billion, marking a 3% increase compared to last year, and surpassing the estimate of $10.69 billion.
- The Life Sciences segment saw revenue of $2.50 billion, a 6.1% rise year-on-year, beating the forecast of $2.44 billion.
- Revenue from Analytical Instruments was $1.73 billion, a decrease of 3% from the previous year, falling short of the projected $1.74 billion.
- The Specialty Diagnostics division reported revenue of $1.13 billion, a 1.5% increase year-on-year, slightly below the estimate of $1.15 billion.
- Lab Products & Services brought in $6.00 billion in revenue, a 4.1% year-on-year increase, surpassing the expected $5.8 billion.
- Revenue eliminations were reported at -$501 million, representing a 6.6% decrease year-on-year, against an estimate of -$477.3 million.
- There was a 1% foreign currency impact on sales compared to a -1% impact the previous year, with an estimated impact of 0.19%.
- Adjusted operating income stood at $2.38 billion, reflecting a 1.2% increase year-on-year, slightly above the $2.3 billion estimate.
- The adjusted operating margin was 21.9%, down from 22.3% year-on-year, but exceeded the estimate of 21.7%.
- Marc N. Casper, CEO of Thermo Fisher Scientific, highlighted the company’s agility and effective cost management contributing to strong operational results.
- Analyst ratings included 25 buys, 5 holds, and no sells.
Thermo Fisher Scientific Inc on Smartkarma
In recent analyst coverage on Smartkarma, Baptista Research has provided bullish insights on Thermo Fisher Scientific Inc. In their report titled “Thermo Fisher Scientific: Latest Expansion in Pharmaceutical Services Driving Our Optimism!,” they highlighted the company’s Q1 2025 earnings report, pointing out both strengths and challenges within the complex macroeconomic landscape. Thermo Fisher Scientific achieved a solid revenue of $10.36 billion and posted an adjusted operating income of $2.27 billion. With an adjusted operating margin of 21.9% and an adjusted EPS of $5.15 reflecting a 1% year-over-year growth, Baptista Research remains optimistic about the company’s performance.
Furthermore, Baptista Research‘s analysis continued with their report “Thermo Fisher Scientific: Will Its Shift Toward Contract Research and Manufacturing Pay Off? – Major Drivers,” focusing on the company’s performance in the fourth quarter of 2024. Thermo Fisher Scientific reported a 5% year-over-year growth in revenue, reaching $11.4 billion, accompanied by a 7% increase in adjusted operating income, reaching $2.72 billion. The company’s adjusted operating margin expanded by 50 basis points to 23.9%, with adjusted earnings per share (EPS) growing by 8% to $6.10. This shift towards contract research and manufacturing positions Thermo Fisher Scientific for potential success, as highlighted by Baptista Research‘s analysis.
A look at Thermo Fisher Scientific Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Thermo Fisher Scientific Inc, a leading manufacturer of scientific instruments and chemicals, has been rated across various factors using Smartkarma Smart Scores. With a solid overall outlook, the company scores well in resilience, indicating its ability to withstand market fluctuations and challenges. Furthermore, Thermo Fisher Scientific also fares well in terms of value and growth, suggesting a potential for long-term stability and development in the market. While the company’s scores for dividends and momentum are not as high, its strengths in resilience, value, and growth bode well for its future prospects in the scientific instruments industry.
Thermo Fisher Scientific, Inc. stands as a key player in providing a wide range of scientific products and services to various sectors including pharmaceutical, biotech, and research institutions. With a focus on manufacturing analytical instruments, laboratory equipment, software, and consumables, the company caters to the needs of hospitals, clinical labs, universities, and government agencies. The company’s Smartkarma Smart Scores indicate a positive outlook, particularly in resilience, value, and growth, showcasing its potential for sustained success and innovation in the scientific instruments market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
